MedPlus reins in staff incentives after aggressive private-label medicine selling
MedPlus Health Services has scaled back staff incentives that encouraged aggressive recommendations of its private-label medicines. The pharmacy chain plans to shift promotion to advertising, influencers and staff training, with private-label mix expected to stabilise this quarter before gradually recovering.
What happened
MedPlus Health Services · MedPlus scaled back staff incentives that led to aggressive private-label medicine recommendations. The pharmacy retailer will instead
Why this matters
MedPlus’s move toward brand-led private-label promotion makes marketing, digital-health and consumer-engagement capabilities more strategically valuable than purely sales-incentive-led distribution assets.
What to watch
- Private-label mix stabilising or recovering in the current quarter versus prior-quarter declines.
- Changes in gross margin, pharmacy basket size and branded-medicine share.
- Customer complaint rates, social-media sentiment and any regulator commentary on staff sales incentives.
- Marketing spend increases, influencer partnerships and loyalty-program offers for private-label medicines.
- Competitor changes to pharmacist incentives, private-label promotion policies or recommendation disclosures.
- Redirect incentive budget into digital, catalogue, loyalty-app and in-store private-label campaigns.
- Create pharmacist and front-of-store training focused on product equivalence, value messaging and appropriate recommendation standards.
- Use loyalty data to target private-label offers to repeat buyers rather than relying on point-of-sale upselling.
- Strengthen packaging, clinical-information content and quality proof points to make private-label medicines more independently discoverable.
- Track private-label conversion, customer complaints, branded-product substitution and basket margin by store following the incentive rollback.